Interne link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome maart 17, 2021 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference maart 02, 2021 om 09:30 PM UTC
Interne link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results februari 25, 2021 om 12:00 PM UTC
Interne link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome februari 16, 2021 om 09:30 PM UTC
Interne link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 januari 07, 2021 om 12:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference november 21, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board november 09, 2017 om 12:00 PM UTC
Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference oktober 24, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference oktober 06, 2017 om 11:00 AM UTC
Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis september 25, 2017 om 08:00 PM UTC
Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology september 21, 2017 om 11:05 AM UTC
Interne link ProQR to Present at Two Investor Conferences in September september 21, 2017 om 11:00 AM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences september 19, 2017 om 11:00 AM UTC
Interne link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics september 12, 2017 om 11:00 AM UTC
Interne link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA september 05, 2017 om 11:00 AM UTC
Interne link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial augustus 29, 2017 om 11:00 AM UTC
Interne link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong augustus 28, 2017 om 11:00 AM UTC